ID   COG-LL-317h
AC   CVCL_M160
DR   Wikidata; Q54813970
RX   PubMed=22137317;
RX   PubMed=26080839;
WW   https://www.cccells.org/tables/Lymp_N.php
CC   Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
CC   Characteristics: Hypoxic cell line grown at 5% O2.
CC   Doubling time: 19-20 hours (COG).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): COG
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 8,12
ST   D16S539: 9,11
ST   D18S51: 14,18
ST   D19S433: 14,16
ST   D21S11: 30
ST   D2S1338: 17,18
ST   D3S1358: 16,17
ST   D5S818: 11,13
ST   D7S820: 11,13
ST   D8S1179: 15
ST   FGA: 20,23
ST   TH01: 7,8
ST   TPOX: 8,11
ST   vWA: 16,17
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_M159 ! COG-LL-317
SX   Male
AG   1Y7M
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 05-10-23; Version: 14
//
RX   PubMed=22137317; DOI=10.1016/j.leukres.2011.10.022;
RA   Zhang C., Ryu Y.-K., Chen T.Z., Hall C.P., Webster D.R., Kang M.H.;
RT   "Synergistic activity of rapamycin and dexamethasone in vitro and in
RT   vivo in acute lymphoblastic leukemia via cell-cycle arrest and
RT   apoptosis.";
RL   Leuk. Res. 36:342-349(2012).
//
RX   PubMed=26080839; DOI=10.1158/1078-0432.CCR-15-0114;
RA   Hall C.P., Reynolds C.P., Kang M.H.;
RT   "Modulation of glucocorticoid resistance in pediatric T-cell acute
RT   lymphoblastic leukemia by increasing BIM expression with the PI3K/mTOR
RT   inhibitor BEZ235.";
RL   Clin. Cancer Res. 22:621-632(2016).
//